Affimed (AFMD) Downgraded to “Hold” at Zacks Investment Research

Share on StockTwits

Zacks Investment Research cut shares of Affimed (NASDAQ:AFMD) from a buy rating to a hold rating in a research note published on Friday.

According to Zacks, “Affimed Therapeutics B.V. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology. The Company’s TandAbs has the ability to bring NK-cells or T-cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Its product pipeline includes AFM13, AFM11 and AFM21. Affimed Therapeutics B.V. is headquartered in Heidelberg, Germany. “

Several other analysts also recently issued reports on the stock. Jefferies Financial Group raised shares of Affimed from a hold rating to a buy rating and upped their price objective for the stock from $1.80 to $4.00 in a report on Tuesday, August 28th. BidaskClub raised shares of Affimed from a strong sell rating to a sell rating in a report on Friday, August 31st. BMO Capital Markets decreased their price objective on shares of Affimed from $6.00 to $4.00 and set an outperform rating for the company in a report on Thursday, August 9th. ValuEngine raised shares of Affimed from a buy rating to a strong-buy rating in a report on Tuesday, August 28th. Finally, SunTrust Banks decreased their price objective on shares of Affimed to $5.00 and set a buy rating for the company in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Affimed currently has an average rating of Hold and an average target price of $4.81.

Shares of NASDAQ AFMD traded down $0.16 during trading hours on Friday, hitting $4.06. 845,659 shares of the stock were exchanged, compared to its average volume of 920,981. The company has a current ratio of 5.36, a quick ratio of 5.33 and a debt-to-equity ratio of 0.06. The company has a market cap of $247.07 million, a P/E ratio of -5.21 and a beta of 3.62. Affimed has a one year low of $1.15 and a one year high of $7.35.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.05). The firm had revenue of $0.36 million for the quarter, compared to the consensus estimate of $0.30 million. Affimed had a negative return on equity of 77.87% and a negative net margin of 2,124.72%. Equities research analysts forecast that Affimed will post -0.64 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new stake in Affimed in the 1st quarter valued at $4,731,000. FMR LLC bought a new stake in Affimed in the 3rd quarter valued at $5,552,000. EAM Global Investors LLC bought a new stake in Affimed in the 3rd quarter valued at $2,064,000. Dimensional Fund Advisors LP boosted its holdings in Affimed by 28.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 319,871 shares of the biopharmaceutical company’s stock valued at $592,000 after purchasing an additional 71,545 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in Affimed by 38.8% in the 2nd quarter. Renaissance Technologies LLC now owns 177,510 shares of the biopharmaceutical company’s stock valued at $293,000 after purchasing an additional 49,610 shares during the period. 40.62% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.

Recommended Story: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Affimed (AFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Amphastar Pharmaceuticals’  Buy Rating Reaffirmed at Wells Fargo & Co
Amphastar Pharmaceuticals’ Buy Rating Reaffirmed at Wells Fargo & Co
Affimed  Downgraded to “Hold” at Zacks Investment Research
Affimed Downgraded to “Hold” at Zacks Investment Research
Preferred Apartment Communities  Lowered to “Sell” at Zacks Investment Research
Preferred Apartment Communities Lowered to “Sell” at Zacks Investment Research
Extraction Oil & Gas  Debt Trading 2.3% Lower
Extraction Oil & Gas Debt Trading 2.3% Lower
Opera  Sees Strong Trading Volume
Opera Sees Strong Trading Volume
IoTeX 24-Hour Trading Volume Reaches $527,224.00
IoTeX 24-Hour Trading Volume Reaches $527,224.00


Leave a Reply

© 2006-2018 Ticker Report